Similar reduction in new cases of type 2 diabetes with angiotensin receptor blocker and ace inhibitor: Comparison of meta-analyses of prospective randomised trials;Réduction comparable des nouveaux cas de diabète de type 2 sous sartan et sous inhibiteur de l'enzyme de conversion de l'angiotensine: Comparaison des méta-analyses des essais prospectifs randomisés

Revue Medicale de Liege

Volumn 60, Issue 5-6, 2005, Pages 424-428

  Scheen, A J ^a,b,c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Service de Diabetologie Nutrition et Maladies Metaboliques   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

ACE inhibitor; ATI receptor blacker; Congestive heart failure; Diabetes mellitus; Evidence based medicine; Hypertension; Meta analysis; Prevention

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; RAMIPRIL; THIAZIDE DIURETIC AGENT; VALSARTAN;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; DIABETES MELLITUS, TYPE 2; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN;

EID: 21744461224     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Scheen AJ.- L'"épidémie" des maladies métaboliques, un problème majeur de santé publique. Rev Med Liège, 1999, 54, 87-94.
2. American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases.- The prevention or delay of type 2 diabetes. Diabetes Care, 2002, 25, 742-749.
3. Scheen AJ, Letiexhe MR, Ernest Ph.- Prévention du diabète de type 2: style de vie ou médicaments? Rev Med Liège, 2003, 58, 206-210.
4. Scheen AJ.- Prévention de l'apparition du diabète de type 2 par l'inhibition du système rénine-angiotensine. Rev Med Liège, 2002, 57, 449-452.
5. Scheen AJ.- Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs, 2004, 64, 2537-2565.
6. Scheen AJ, Estrella F, Weekers L.- Hypertension artérielle et diabète de type 2. Rev Med Liège, 1999, 54, 789-795.
7. Padwal R, Laupacis A.- Antihypertensive therapy and incidence of type 2 diabetes. A systematic review. Diabetes Care, 2004, 27, 247-255.
8. Pepine CJ, Cooper-DeHoff RM.- Cardiovascular therapies and risk for development of diabetes. J Am Coll Cardiol, 2004, 44, 509-512.
9. Opie LH, Schall R.- Old antihypertensives and new diabetes. J Hypertens, 2004, 22, 1453-1458.
10. Grundy SM.- Higher incidence of new-onset diabetes in patients with heart failure. Am J Med, 2003, 114, 331-332.
11. Scheen AJ, Paquot N, Jandrain B.- Comment j'explore ... le risque d'un patient d'évoluer vers un diabète de type 2. Rev Med Liège, 2002, 57, 113-115.
12. Scheen AJ.- VALUE: analysis of results (Letter to the Editor). Lancet, 2004, 364, 932-933.
13. Scheen AJ.- Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diab Metab, 2004, 30.
14. Verdecchia P, Reboldi G, Angeli F, et al.- Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension, 2004, 43, 963-969.
15. Scheen AJ.- Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diab Metab, 2004, 30, 498-505.
16. Fogari R, Zoppi A, Lazzari P, et al.- ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol, 1998, 32, 616-620.
17. Henriksen EJ, Jacob S, Kinnick TR, et al.- ACE inhibition and glucose transport in insulin resistant muscle: roles of bradykinin and nitric oxide. Am J Physiol, 1999, 277, R332-336.
18. Scheen AJ.- Comment j'explore ... les secrets d'une méta-analyse. Rev Med Liege, 2003, 58, 41-46.
19. The ONTARGET/TRANSCEND Investigators.- Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/ Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J, 2004, 148, 52-61.
20. Scheen AJ.- Récepteurs PPAR-γ, nouvelle cible therapeutique dans les pathologies métaboliques et cardiovasculaires. Rev Med Liège, 2005, 60, 89-95.